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Abstract
Introduction Patients requiring prolonged acute mechanical
ventilation (PAMV) represent one-third of those who need
mechanical ventilation, but they utilize two-thirds of hospital
resources devoted to mechanical ventilation. Measures are
needed to optimize the efficiency of care in this population. Both
duration of intensive care unit stay and mechanical ventilation
are associated with anemia and increased rates of packed red
blood cell (pRBC) transfusion. We hypothesized that
transfusions among patients receiving PAMV are common and
associated with worsened clinical and economic outcomes.
Methods A retrospective analysis of a large integrated claims
database covering a 5-year period (January 2000 to December
2005) was conducted in adult patients receiving PAMV
(mechanical ventilation for ≥ 96 hours). The incidence of pRBC
transfusions was examined as the main exposure variable, and
hospital mortality served as the primary outome, with hospital
length of stay and costs being secondary outcomes.
Results The study cohort included 4,344 hospitalized patients
receiving PAMV (55% male, mean age 61.5 ± 16.4 years).
Although hemoglobin level upon admission was above 10 g/dl
in 75% of patients, 67% (n = 2,912) received at least one
transfusion, with a mean of 9.1 ± 12.0 units of pRBCs
transfused per patient over the course of hospitalization. In
regression models adjusting for confounders, exposure to
pRBCs was associated with a 21% increase in the risk for
hospital death (95% confidence interval [CI] = 1.00 to 1.48),
and marginal increases in length of stay (6.3 days, 95% CI = 5.1
to 7.6) and cost ($48,972, 95% CI = $45,581 to $52,478).
Conclusion Patients receiving PAMV are at high likelihood of
being transfused with multiple units of blood at relatively high
hemoglobin levels. Transfusions independently contribute to
increased risk for hospital death, length of stay, and costs.
Reducing exposure of PAMV patients to blood may represent an
attractive target for efforts to improve quality and efficiency of
health care delivery in this population.
Introduction
Patients requiring prolonged acute mechanical ventilation
(PAMV), defined as 96 hours of mechanical ventilation (MV) or
longer, are a group with high hospital utilization intensity [1].
Although constituting roughly one-third of all hospitalized MV
patients, they account for about two-thirds of all the hospital
resources allocated to the MV group [1]. For example, in the
USA in 2003, PAMV patients occupied 6,728,819 hospital
days, at an aggregate annualized hospital cost of over $16 bil-
lion [1]. At the same time their hospital mortality of 35% is sim-
ilar to that observed among ventilated patients who require
fewer than 96 hours of MV. Based on age-adjusted and dis-
ease-specific incidence rates, this population is projected to
more than double by the year 2020, thus mandating increased
emphasis on efficiency of health care delivery to patients
requiring PAMV [2].
Anemia is a frequent complication of critical illness, and its eti-
ology is multifactorial [3-5]. Despite evidence from a large ran-
domized controlled trial suggesting that tolerating a lower
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hemoglobin among critically ill patients results in unimpaired
outcomes, more recent observational data indicate that adher-
ence to this recommendation is poor across the board, and is
worst among patients requiring MV [3,5,6]. At the same time,
a large body of work specifically addressing the critically ill
points to a strong association of exposure to allogeneic blood
with such complications as acute lung injury (ALI), ventilator-
associated pneumonia, and blood stream infection (BSI) [7-
11], and morbidity and attendant hospital resource utilization
stemming from such complications may be avoided by more
restrictive use of allogeneic blood [12-15].
Because by virtue of having a prolonged critical illness the
PAMV population is at greater risk for exposure to packed red
blood cell (pRBC) transfusions [16], we hypothesized that in
this population more liberal use of allogeneic blood is associ-
ated with worse clinical and economic outcomes. Conversely,
it would follow that a more restrictive approach to transfusions
might result in fewer complications, better outcomes, and thus
better quality health care and more efficient health care
delivery.
Materials and methods
Human subjects protection
Approval was obtained from the Institutional Review Board of
the Henry Ford Health System. No informed consent was
required because the study involved the use of de-identified
claims data.
Data source
We performed a retrospective cohort study within the Henry
Ford Health System (HFHS) database. HFHS is a large, verti-
cally integrated health care system that includes seven hospi-
tals serving the primary and specialty health care needs of
residents in the Midwestern USA. The care provided includes
more than 2.5 million patient contacts, 20,000 ambulatory sur-
geries, and 65,000 hospital admissions annually. Most of the
care is provided under system-affiliated, salaried physician
groups with nearly 900 physicians in more than 40 specialties.
Approximately 60% of HFHS members are enrolled in a large
nonprofit, mixed-model health maintenance organization. This
subset population includes a substantial number of both Medi-
care (n = 16,000) and Medicaid (n = 22,000) enrollees.
Cohort identification
In the present analysis we used data from all hospital admis-
sions that took place between January 2000 and December
2005. Patients were included if they were 18 years old or
older and had charges associated with at least one procedure
code for insertion of an endotracheal tube for MV and at least
one code for 96 continuous hours of ventilation. The index
date was defined as the date of the first hospital admission
containing these codes. Patients on dialysis before the index
admission and with a diagnosis code for chronic renal failure
were not included in the analysis. Additional file 1 presents the
inclusion criteria and associated procedure codes for study
patients.
Exposure variables
The primary exposure of interest was transfusion of pRBCs
during the entire period of hospitalization, based on blood
bank data linked to specific patient encounters. A transfusion
episode was identified by the receipt of at least one unit of
pRBCs on any given day of hospitalization. An additional
measure of transfusion exposure was units of RBCs trans-
fused per patient. Transfusion exposure was further stratified
based on the baseline, pretransfusion, and nadir hemoglobin.
Baseline hemoglobin was calculated using the first laboratory
measurement on the date of admission; or, if this was not avail-
able, the last measurement on the day before admission; or, if
none on that day, the first laboratory measurement on the day
after admission. Pretransfusion hemoglobin was defined as
the lowest hemoglobin measured on or the day before the day
of transfusion. Pretransfusion hemoglobin was divided into the
following categories: <7 g/dl, 7 to 8 g/dl, 8 to 9 g/dl, 9 to 10
g/dl, and ≥ 10 g/dl [3]. Nadir hemoglobin was defined as the
lowest hemoglobin recorded for a patient during the inpatient
stay. PAMV patients who received transfused blood were
compared with those who did not, based on demographic and
clinical characteristics. The burden of chronic illness was
assessed using the modified Charlson Comorbidity Index
score [17]. Using International Classification of Diseases,
ninth revision (ICD-9) codes, 16 weighted co-morbidity varia-
bles were defined: a patient's total score (the sum of the
scores from each condition present; maximum 34) indicated
his or her chronic disease burden.
Outcome measures
The primary outcome measure was hospital mortality, com-
pared between transfused and nontransfused PAMV patients.
Resource utilization (hospital length of stay), hospital costs,
discharge hemoglobin, and destination served as the second-
ary outcomes of interest. Although discharge hemoglobin and
destination were examined in a descriptive manner only, hos-
pital mortality, length of stay (LOS) and costs were looked at
in multivariable models (see Statistical analyses, below).
Statistical analyses
Values are expressed as percentages and mean ± standard
deviation, and P < 0.05 was considered to represent statisti-
cal significance.
Frequencies (for categorical variables) and distributions (for
continuous variables), from the index admission date to the
date of hospital discharge, were compared using χ2 and Stu-
dent's  t-tests, respectively, for all normal data stratified by
transfused versus nontransfused patients. Mann-Whitney
tests were applied to hospital LOS and cost to assess the sig-
nificance of differences across exposure to pRBCs. The inde-
pendent contribution of transfusion exposure to hospitalAvailable online http://ccforum.com/content/12/2/R60
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mortality, LOS, and costs was assessed in multivariable mod-
els. Although hospital mortality was examined in a logistic
regression, the attributable hospital LOS and costs were com-
puted in linear regressions. Because both LOS and costs have
highly skewed distributions, the values were log-transformed
for the models, and the resultant coefficients were retrans-
formed using the Duan smearing method [18] to yield incre-
mental days and dollars, respectively. The co-variates initially
included in the multivariate analyses were patient demograph-
ics (age, sex, and race), comorbidities (Charlson Comorbidity
Index score), and baseline and nadir hemoglobin levels. Addi-
tional variables examined as potential confounders of the rela-
tionship between transfusion exposure and outcomes were
such complications as hospital-acquired pneumonia (HAP)
and BSI (based on the presence of an ICD-9-CM code for
pneumonia, bacteremia, or septicemia; see Additional file 1).
Finally, potential confounding by such markers of blood loss as
gastrointestinal endoscopy, or such surgical procedures as
abdominal, cardiac (on-pump and off-pump), and orthopedic
surgeries was examined. Those covariates with P > 0.2 were
eliminated in a manual backward selection process. Diagnos-
tics were performed to ensure the validity of each final model.
Results
Cohort characteristics
We identified 4,344 hospitalized patients with PAMV during
the time frame examined. Most members of the study popula-
tion were male (54.5%) and African-American (57.6%), with
the mean age being 61.5 ± 16.4 years and the mean Charlson
Comorbidity Index score being 7.3 ± 3.6.
The transfusion rate in the cohort was 67.0% (n = 2,912).
Transfused patients were older (62.0 ± 16.5 years versus
60.4 ± 16.2 years; P = 0.0014), more likely to be female
(46.8% versus 42.9%; P = 0.018), had a significantly higher
chronic disease burden (Charlson Comorbidity Index scores
of 7.8 ± 3.6 versus 6.2 ± 3.3; P < 0.0001), a lower mean
baseline hemoglobin (11.1 ± 2.4 g/dl versus 13.0 ± 2.0 g/dl;
Table 1
Baseline demographic and clinical characteristics of patients on PAMV by transfusion status
Characteristic Transfused (n = 2,912) Nontransfused (n = 1,432) P value
Sex (% female) 46.8 42.9 0.018
Age (years; mean ± SD) 62.0 ± 16.5 60.4 ± 16.2 0.0014
Race (%)
African American 55.5 61.9 <0.0001
Caucasian 36.9 32.7
Other 8.6 5.4
Chronic concomitant comorbidities, %
Cardiac disease 88.0 79.8 <0.0001
Hypertension 69.4 65.9 0.02
Anemia 64.7 22.8 <0.0001
Pulmonary disease 64.6 65.9 0.43
Gastrointestinal disease 57.6 31.1 <0.0001
Central nervous system disease 50.8 44.8 0.0002
Cancer 39.1 26.1 <0.0001
Immunologic disease 38.9 22.8 <0.0001
Thromboembolic disease 38.5 30.0 <0.0001
Renal disease 35.3 15.8 <0.0001
Diabetes 31.6 26.1 0.0002
Musculoskeletal disease 31.4 14.6 <0.0001
Peripheral vascular disease 29.2 26.9 <0.0001
Cerebrovascular disease 28.7 21.7 0.11
Primary hematologic disease 15.2 7.5 <0.0001
PAMV, prolonged acute mechanical ventilation; SD, standard deviation.Critical Care    Vol 12 No 2    Zilberberg et al.
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P < 0.0001), and a lower mean nadir hemoglobin (7.3 ± 1.1
g/dl versus 9.9 ± 1.7 g/dl; P < 0.0001) than did those who did
not require a transfusion (Table 1). The distribution of the top
5 admitting diagnoses is shown in Table 2. Acute respiratory
failure was the most frequent admitting diagnosis in both
patient groups, namely those who required a transfusion and
those who did not (5.1% versus 12.4%).
Hemoglobin and transfusions
The total number of transfusion episodes during the index
admission was 7,787 among 2,912 transfused patients. Each
patient who was transfused received an average of 3.2 ± 2.8
units/transfusion episode and a total 9.1 ± 12.0 units of blood
over the course of the hospitalization. Mean pretransfusion
hemoglobin for the 7,787 transfusion episodes was 8.2 ± 1.4
g/dl. The majority of transfusion episodes (69% total)
occurred at pretransfusion hemoglobin levels 7 to <8 g/dl
(35%; mean units of blood/transfusion episode 3.1 ± 2.9) and
8 to <9 g/dl (34%; mean units of blood/transfusion episode
3.0 ± 3.6; Figure 1). Only 12% of all transfusion episodes in
the cohort occurred at the pretransfusion hemoglobin below 7
g/dl, and in this group the mean number of units/transfusion
episode was high (5.3 ± 6.5). Conversely, 7% of the episodes
occurred in the setting of a pretransfusion hemoglobin above
10 g/dl.
Outcomes
Crude hospital mortality was significantly higher among PAMV
patients who underwent transfusion as compared with those
who did not (odds ratio [OR] = 1.51, 95% confidence interval
[CI] = 1.31 to 1.75; P < 0.0001). Compared with nontrans-
fused patients, transfused patients were also more likely to
experience HAP (OR = 1.63, 95% CI = 1.38 to 1.93) or BSI
(OR = 2.90, 95% CI = 2.53 to 3.34; P < 0.0001 for each) and
to have undergone a procedure serving as a marker of high
bleeding risk (P < 0.0001 for all five procedures). Similarly,
transfused patients had a significantly greater hospital LOS
and corresponding total hospital costs than did nontransfused
patients (Table 3). Of the patients discharged alive, the odds
of being discharged directly home were significantly lower
among those transfused (OR = 0.38, 95% CI = 0.32 to 0.44;
P < 0.0001) than those who were not transfused. Conversely,
a discharge to an intermediate health care facility was 2.64
(95% CI = 2.25 to 3.11; P < 0.0001) times as likely in the
transfused group. Finally, despite a high transfusion rate, those
transfused were discharged with significantly lower hemo-
globin than those who did not receive any transfusions (9.8 ±
1.4 g/dl versus 10.8 ± 1.8 g/dl; P < 0.0001; Table 3).
Regression modeling confirmed the independent contribution
of pRBC transfusions to hospital mortality, LOS, and aggre-
gate costs of hospitalization. Thus, in a logistic regression,
exposure to allogeneic blood was associated with a 21%
(95% CI = 1.00 to 1.48) increase in the risk of death, and lin-
ear models suggested that transfusions alone were responsi-
ble for a marginal 6.3 (95% CI = 5.12 to 7.62) day increase in
hospital LOS and $48,972 (95% CI = $45,582 to $52,478)
increase in hospital costs (Table 4).
Discussion
In the present study we have demonstrated that transfusions
are commonly used among patients requiring PAMV, occur at
relatively liberal hemoglobin triggers, and are associated with
worsened hospital outcomes, including mortality, LOS, and
costs. We have also shown that PAMV patients undergoing a
transfusion are less likely to be discharged home and, despite
a high transfusion burden, leave the hospital with a lower
hemoglobin level than those not undergoing a transfusion.
Specifically, we have documented a 67% transfusion rate
Table 2
Distribution of top 5 primary diagnoses among patients on PAMV by transfusion status
Admitting diagnoses (%) Transfused (n = 2,912) Nontransfused (n = 1,432)
Acute respiratory failure 5.1 12.4
Heart failure 4.1 6.1
Subendocardial AMI 4.0 3.4
Pneumonia 3.7 5.0
Intracerebral hemorrhage 2.3 3.6
AMI, acute myocardial infarction; PAMV, prolonged acute mechanical ventilation.
Figure 1
Transfusion episodes occurring at each level of pretransfusion hemo- globin among transfused patients on PAMV Transfusion episodes occurring at each level of pretransfusion hemo-
globin among transfused patients on PAMV. Hb, hemoglobin; PAMV, 
prolonged acute mechanical ventilation.Available online http://ccforum.com/content/12/2/R60
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among these patients, with the attendant attributable mortality,
LOS, and cost increases of 21%, 6.3 days, and $48,972,
respectively. Importantly, these numbers reflect the adjust-
ment for potential contributions to these outcomes of such
high risk and costly events as nosocomial infections (HAP and
BSI) and gastrointestinal bleeding, and cardiac, abdominal
and orthopedic surgeries.
Table 3
Hospital events and unadjusted outcomes among patients on PAMV by transfusion status
Events and outcomes Transfused (n = 2,912) Nontransfused (n = 1,432) P value
Complications (%)
Pneumonia 86.2 79.3 <0.0001
Blood stream infection 49.7 20.1 <0.0001
Tracheostomy 71.9 69.8 0.16
Processes of care
Gastrointestinal endoscopy 31.2 12.4 <0.0001
Abdominal surgery 47 18.4 <0.0001
Cardiac surgery (on-pump) 9.2 0.7 <0.0001
Cardiac surgery (off-pump) 9.9 2.7 <0.0001
Orthopedic surgery 9.3 1.8 <0.0001
Hospital mortality (%) 32.2 23.9 <0.0001
Discharge destination (n [%])
Home 433 (22.0) 465 (42.7) <0.0001
Skilled nursing facility 496 (25.1) 200 (18.4)
Rehabilitation center 382 (19.4) 143 (13.1)
Home health service 275 (13.9) 147 (13.5)
Rehabilitation with long-term ventilator care 150 (7.6) 39 (3.6)
Hospice 52 (2.6) 20 (1.8)
Other health facility 151 (7.7) 47 (4.3)
Other/unknown 34 (1.7) 29 (2.7)
Hemoglobin (mean ± SD)
Baseline 11.1 ± 2.4 13.0 ± 2.0 <0.0001
Nadir 7.3 ± 1.1 9.9 ± 1.7 <0.0001
Discharge 9.8 ± 1.4 10.8 ± 1.8 <0.0001
LOS
Mean ± SD 29.6 ± 22.5 15.5 ± 10.9 <0.0001
25th percentile 15 9
50th percentile 24 13
75th percentile 37 19
Charges
Mean ± SD 101,828 ± 72,925 239,312 ± 187,882 <0.0001
25th percentile 55,294 115,870
50th percentile 83,537 185,542
75th percentile 126,623 294,389
LOS, length of stay; PAMV, prolonged acute mechanical ventilation; SD, standard deviation.Critical Care    Vol 12 No 2    Zilberberg et al.
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Health care costs in the USA have reached an unprecedented
$2.1 trillion, representing 16% of the gross domestic product
[19]. A large proportion of this price tag, approximately one-
third, is attributed to hospital expenses, and these have been
rising steadily [20]. The intensive care unit (ICU), in turn, is a
high-intensity use area of the hospital, whose utilization by the
Medicare population alone has grown by over 12% in a recent
5-year period [21]. MV, whose attributable cost is $1,500/day
in 2002 US dollars, is the single greatest driver of the ICU
costs [22]. Illustrating this, the 2003 aggregate hospital costs
for all patients undergoing any MV were $25 billion, 64% of
which (or $16 billion) was consumed by patients requiring
PAMV [1]. Furthermore, given the historic approximately 6%
crude annual growth in the volume of PAMV in US hospitals,
age-specific incidence change in PAMV over time, and the
age-adjusted US population growth, PAMV patients are likely
to number over 600,000 cases by year 2020, more than dou-
bling their current numbers [2]. Such substantial utilization of
health care resources demands closer scrutiny.
Given that hospital survival rate among patients on PAMV is
comparable to that among patients requiring shorter term ven-
tilatory support [1], institution of measures that are directed at
optimizing efficiency of health care delivery to this population
are critical. Allogeneic blood transfusion is one area of health
care delivery in which the penetration of evidence-based prac-
tices has remained suboptimal [3,5]. Despite the fact that a
randomized controlled trial performed a decade ago confirmed
safety of reducing hemoglobin transfusion triggers among crit-
ically ill from the traditional 10 g/dl to 7 g/dl [23], the mean pre-
transfusion hemoglobin remains in the region of 8.5 g/dL
among all ICU patients, and is even higher among those
requiring MV [3,5,6]. Our study demonstrates nonadherence
not only to this recommendation but also to the guidance sup-
porting the administration of only 1 unit of pRBCs per transfu-
sion episode, as was done in the TRICC (Transfusion
Requirements in Critical Care) trial [23], because we have
observed that on average a transfused PAMV patient receives
more than 3 units of blood in a single transfusion episode.
Unfortunately, this nonadherence to recommendations based
on the best evidence is not without consequences. Evidence
points to a strong association between exposure to blood
transfusions and such complications as ventilator-associated
pneumonia and BSIs [9,10,24], as well as multiple other infec-
tious and immune complications [25-27]. Evidence for the
connection between acute respiratory distress syndrome
(ARDS) and transfusion exposure is also mounting. For exam-
ple, not only did the difference in the ARDS incidence nearly
reach statistical significance in the TRICC trial (P = 0.06), with
the more favorable results in the restrictive arm [23], but also
several prospective cohort studies have strengthened this
association [7,8,11], particularly because some were able to
detect a dose-response relationship between the magnitude
of blood exposure and risk for subsequent development of
ARDS [7,11]. Giving further credence to this causal relation-
ship is a recent report from the Mayo clinic [13], in which
adherence to a restrictive transfusion protocol along with the
use of a lung-protective ventilation strategy resulted in a reduc-
tion in ALI incidence from 28% to 10%. In general, it is esti-
mated that adopting restrictive triggers more ubiquitously
could result in avoidance of nearly 40,000 acute complica-
tions associated with transfusions, and, more specifically,
approximately 17,000 cases of ARDS alone [14,15]. This may
even be an under-estimate, given the results of the nested
case-control study conducted by Gajic and coworkers [28], in
which ALI was prospectively observed in 8% of all patients
exposed to blood products. Our study, by focusing on the
population of MV patients at greatest risk for transfusions
(namely those receiving PAMV), deepens our understanding
not only of transfusion practices in PAMV patients but also of
how altering these practices in line with the best evidence
might result in lower costs and better outcomes for patients.
Given that more than a half of all of the observed transfusion
episodes were administered at or above a hemoglobin con-
centration of 8 g/dl, and given the noted contribution of alloge-
neic pRBC exposure to mortality, hospital LOS, and costs in
the PAMV population, there is a substantial opportunity to
improve these outcomes via an evidence-driven reduction in
transfusion triggers.
Our study has a number of limitations. First, its retrospective
nature lends itself to multiple forms of bias, the most important
of which is a selection bias. We have mitigated this possibility
by employing uniform inclusion criteria that are based on a
strict definition of the population, as well as by following all
Table 4
Mortality, hospital LOS, and costs attributable to transfusion exposure among patients on PAMV
Variable Adjusted estimate 95% confidence interval
Hospital mortality (adjusted odds ratio) 1.21 1.00 to 1.48
Hospital LOS (days) 6.33 5.12 to 7.62
Hospital costs ($) $48,973 $45,582 to $52,478
Each estimate adjusted for the following confounding variables: age, sex, race, Charlson Comorbidity Index, baseline and nadir hemoglobin, 
hospital-acquired pneumonia, blood stream infection, gastrointestinal endoscopy, abdominal surgery, cardiac surgery (on and off bypass), and 
orthopedic surgery. Mortality outcomes were adjusted additionally for hospital LOS. Hospital LOS and cost outcomes were adjusted for mortality. 
LOS, length of stay; PAMV, prolonged acute mechanical ventilation.Available online http://ccforum.com/content/12/2/R60
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patients to the hard end-points of hospital discharge or death.
Second, having been performed in a single health care system,
the underlying population characteristics may limit the gener-
alizability of our findings. Third, the accuracy of the identifica-
tion of hospital complications (HAP and BSI) and such
processes of care as the surgical procedures we adjusted for
may be at least somewhat questionable, because we utilized
administrative coding, and not clinical data, to define these
conditions. Although it is possible that the first two are prone
to being over-reported in the hospital's billing system, particu-
larly for the sicker patients, the reporting of surgical proce-
dures is less likely to have an inherent bias. Fourth, because of
its observational nature, and although we attempted to adjust
for confounders, the possibility of residual confounding
remains. Finally, our study was performed before widespread
utilization of leukoreduction, and thus it may overestimate the
association between transfusions and such adverse outcomes
as infectious complications or ALI. However, this potential
inflation of the association, if present, is likely to be small,
because a recent randomized controlled trial failed to observe
a reduction in the incidence of either infection or ALI in the
group exposed to leukoreduced blood [29,30].
Conclusion
In summary, we have demonstrated that two-thirds of all
patients on PAMV are exposed to allogeneic blood during their
hospitalization. Furthermore, the total amount of blood is, on
average, a staggering 9 units per transfused patient. Even with
a pretransfusion hemoglobin of >7 g/dl, the number of units
administered per one episode of transfusion is over 3. This
potential overuse of allogeneic blood is associated with a 21%
increase in adjusted hospital mortality, and an incremental
hospital LOS and costs of 6.3 days and $48,972, respec-
tively. Our data support the idea that evidence-based transfu-
sion practices in this population of critically ill patients may be
one of the ways to improve quality and efficiency of health care
delivery.
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